Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 7.38 above company average Quick Ratio.

Within Legal Cannabis industry only one company has achieved higher Quick Ratio in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from to 358.

Explain Quick Ratio?
How much Cash & cash equivalents RGC´s has?
What are RGC´s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

RGC Quick Ratio	(Jun 30 2025) Q4	0 Q3	0 Q2	0 Q1	(Jun 30 2023) Q4
Y / Y Current Liabilities Change	9.36 %	9.36 %	9.36 %	9.36 %	5.04 %
Y / Y Cash & cash equivalent Change	-57.66 %	-57.66 %	-57.66 %	-57.66 %	-29.56 %
Quick Ratio MRQ	7.38	7.38	7.38	7.38	19.06
RGC's Total Ranking	# 358	#	#	#	#
Seq. Current Liabilities Change	0 %	0 %	0 %	9.36 %	0 %
Seq. Cash & cash equivalent Change	0 %	0 %	0 %	-57.66 %	0 %

New: More RGC's historic Quick Ratios >>

Quick Ratio fourth quarter 2025 Company Ranking
Within:	No.
Legal Cannabis Industry	# 2
Consumer Non Cyclical Sector	# 5
Overall Market	# 358

Quick Ratio Statistics
High	Average	Low
28.41	5.99	0.01
(Jun 30 2022)		(Jun 30 2021)

Financial Statements
Regencell Bioscience Holdings Limited's Current Liabilities	$ 1 Millions	Visit RGC's Balance sheet
Regencell Bioscience Holdings Limited's Cash & cash equivalent	$ 5 Millions	Visit RGC's Balance sheet
Source of RGC's Sales		Visit RGC's Sales by Geography

Cumulative Regencell Bioscience Holdings Limited's Quick Ratio

RGC's Quick Ratio for the trailling 12 Months

RGC Quick Ratio	(Jun 30 2025) 12 Months	0 12 Months	0 12 Months	0 12 Months	(Jun 30 2023) 12 Months
Y / Y Current Liabilities TTM Growth	9.36 %	8.32 %	7.25 %	6.16 %	5.04 %
Y / Y Cash & cash equivalent TTM Growth	-57.66 %	-48.63 %	-41.17 %	-34.9 %	-29.56 %
Quick Ratio TTM	7.38	10.11	12.96	15.94	19.06
Total Ranking TTM	# 2812	#	#	#	#
Seq. Current Liabilities TTM Growth	2.19 %	2.24 %	2.29 %	2.34 %	1.21 %
Seq. Cash & cash equivalent TTM Growth	-25.4 %	-20.25 %	-16.84 %	-14.41 %	-9.49 %

Quick ratio ranking by company, industry and sector >> Back to RGC Financial Strength Comparisons >> Go to Compare RGC Quick Ratio to its Competitors

On the trailing twelve months basis Due to unchanged in Current Liabilities in the Q4 2025 to $0.66 millions, cumulative Quick Ratio decreased to 7.38 above the RGC average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Legal Cannabis industry 10 other companies have achieved higher Quick Ratio than Regencell Bioscience Holdings Limited. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from to 2812.

Explain Quick Ratio?
How much Cash & cash equivalents RGC´s has?
What are RGC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Legal Cannabis Industry	# 11
Consumer Non Cyclical Sector	# 119
Within the Market	# 2812

trailing twelve months Quick Ratio Statistics
High	Average	Low
28.41	5.68	0.01
(Jun 30 2022)		(Jun 30 2021)

Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Legal Cannabis Industry	Quick Ratio	Jun 30 2025 MRQ Cash & cash equivalent	Jun 30 2025 MRQ Current Liabilities
Mind Medicine mindmed Inc	9.62	$ 182.993 Millions	$ 19.013 Millions
Regencell Bioscience Holdings Limited	7.38	$ 4.897 Millions	$ 0.664 Millions
Canopy Growth Corporation	1.51	$ 114.484 Millions	$ 75.581 Millions

Date modified: 2025-11-01T05:56:14+00:00

Help

About us

Terms of Use

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.